However, the available treatments for PMF typically include corticosteroids, androgens, erythropoietin-stimulating agents (ESAs), and immunomodulatory drugs for managing MF-related anemia; hydroxyurea for managing symptomatic splenomegaly; and JAK inhibitors (such as ruxolitinib, fedratinib, and pacritinib) for managing splenomegaly or other symptoms with anemia. This evidence concerns the gene EPO and Splenomegaly.